Biomea Fusion Inc (BMEA) News

Form PRE 14A - Other preliminary proxy statements

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Mick Hitchcock, Ph.D., appointed Interim Chief Executive OfficerBiomea preparing icovamenib for late-stage...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Biomea Fusion Announces Leadership Transition

Board member Mick Hitchcock, named interim CEO replacing Thomas Butler. COO and President Ramses Erdtmann...

Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose

Therapeutic effects were sustained off treatment, with persistent reduction in HbA1c and improvement in...

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a...

Form 8-K - Current report

Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes

REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a...

Form 8-K - Current report

Biomea Fusion to Become a Diabetes & Obesity Medicines Company

Icovamenib & BMF-650 (oral small molecule GLP-1) are the cornerstones of the metabolic franchiseBiomea...

Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide...